Coherus Oncology, Inc. (CHRS) vs Nkarta, Inc. (NKTX)
A side-by-side comparison of Coherus Oncology, Inc. and Nkarta, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
NKTX
Nkarta, Inc.
$2.42HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
Total return — CHRS vs NKTX
growth of $100 · dividends reinvested · last 6yCHRS -93.8% (-37.1%/yr)NKTX -94.7% (-38.7%/yr)CHRS compounded faster over this window
CHRS NKTX
CHRS vs NKTX: by the numbers
- •NKTX is the larger company ($173M vs $165M market cap).
- •Both run net losses; NKTX's is the smaller (0.00% vs -257.10% net margin).
Metrics side by side
Valuation
| Metric | CHRS | NKTX |
|---|---|---|
| P/S ratio | 3.23 | N/A |
| P/B ratio | 2.70 | 0.70 |
Profitability
| Metric | CHRS | NKTX |
|---|---|---|
| Gross margin | 63.55% | 0.00% |
| Operating margin | -425.72% | 0.00% |
| Net margin | -257.10% | 0.00% |
| ROE | -215.26% | -47.36% |
| ROIC | -135.38% | -42.11% |
Growth (annualized)
| Metric | CHRS | NKTX |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | N/A |
| Total return CAGR (5Y) | -41.38% | -37.28% |
Frequently asked
- How have CHRS and NKTX total returns compared?
- Over the past 5 years, CHRS delivered -41.38% and NKTX delivered -37.28% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.